Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34894 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Michael Masetti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, Munich, Germany. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Themen: Onkologische Pflege
Abstract (Originalsprache)
FOLFOX plus nivolumab represents a standard of care for first‐line therapy of advanced gastroesophageal cancer (aGEC) with positive PD‐L1 expression. The efficacy of second‐line VEGFR‐2 inhibition with ramucirumab (RAM) plus chemotherapy after progression to immunochemotherapy remains unclear. Medical records of patients with aGEC enrolled in the randomized phase II AIO‐STO‐0417 trial after treatment failure to first‐line FOLFOX plus nivolumab and ipilimumab were retrospectively analyzed. Patients were divided into two groups based on second‐line therapy: RAM plus chemotherapy (RAM group) or treatment without RAM (control group). Eighty three patients were included. In the overall population, progression‐free survival (PFS) in the RAM group was superior to the control (4.5 vs 2.9 months). Responders (CR/PR) to first‐line immunochemotherapy receiving RAM containing second‐line therapy had prolonged OS from start of first‐line therapy (28.9 vs 16.5 months), as well as second‐line OS (9.6 vs 7.5 months), PFS (5.6 vs 2.9 months) and DCR (53% vs 29%) compared to the control. PD‐L1 CPS ≥1 was 42% and 44% for the RAM and the control, respectively. Patients with CPS ≥1 in the RAM group showed better tumor control (ORR 25% vs 10%) and improved survival (total OS 11.5 vs 8.0 months; second‐line OS 6.5 vs 3.9 months; PFS 4.5 vs 1.6 months) compared to the control. Prior exposure to first‐line FOLFOX plus dual checkpoint inhibition followed by RAM plus chemotherapy shows favorable response and survival rates especially in patients with initial response and positive PD‐L1 expression and has the potential to advance the treatment paradigm in aGEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, Munich, Germany.
- Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt, Germany and Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt, Germany.
- Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Klinik für Innere Medizin, Universitätsklinikum Marburg, Marburg, Germany.
- Haematologisch-Onkologische Praxis Eppendorf, Universitäres Cancer Center Hamburg (UCCH), Hamburg, Germany.
- Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
ORCID-Profile: Michael Masetti, Thomas Jens Ettrich, Maria Loose, Sylvie Lorenzen
Förderung
- Eli Lilly and Company
Zitieren
APA
Masetti, M., Al-Batran, S. E., Goetze, T. O., Thuss-Patience, P., Knorrenschild, J. R., Goekkurt, E., Folprecht, G., Ettrich, T. J., Lindig, U., Luley, K. B., Pink, D., Dechow, T., Sookthai, D., Junge, S., Loose, M., Pauligk, C., & Lorenzen, S. (2024). Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.34894
Vancouver
Masetti M, Al-Batran SE, Goetze TO, Thuss-Patience P, Knorrenschild JR, Goekkurt E, et al. Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy. International Journal of Cancer. 2024. doi:10.1002/ijc.34894
BibTeX
@article{Masetti2024,
author = {Masetti, Michael and Al-Batran, Salah-Eddin and Goetze, Thorsten O and Thuss-Patience, Peter and Knorrenschild, Jorge Riera and Goekkurt, Eray and Folprecht, Gunnar and Ettrich, Thomas Jens and Lindig, Udo and Luley, Kim Barbara and Pink, Daniel and Dechow, Tobias and Sookthai, Disorn and Junge, Sabine and Loose, Maria and Pauligk, Claudia and Lorenzen, Sylvie},
title = {Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34894}
}
EUVIMED